Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of risk factors for hospital-onset bacteremia to inform a routine data based risk prediction - an umbrella review.

The Journal of hospital infection·2026

Same author

Effects of a clinical metagenomics intervention on clinical outcomes, healthcare costs, and health-related quality of life in patients with sepsis or septic shock: results of the randomized-controlled DigiSep trial.

Intensive care medicine·2026

Same author

Impact of generic market entry on the consumption of last-resort antibiotics in six European countries.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Same author

Interhospital Transfers in ICU- and Non-ICU-Treated Sepsis Patients in Germany Between 2016 and 2019.

Critical care explorations·2026

Same author

Microbial cell-free DNA for rapid pathogen identification in clinical diagnostics: a proof of concept study.

Genome medicine·2026

Same author

Real-World Data on the Use of Intravenous Fosfomycin for the Treatment of Central Nervous System Infections: a Subgroup Analysis from the FORTRESS Study.

Infectious diseases and therapy·2026

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 29, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumococcal vaccination].

Mathias W Pletz¹, Christina Bahrs^2,3

¹Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Friedrich-Schiller-Universität, Am Klinikum 1, 07747, Jena, Deutschland. mathias.pletz@med.uni-jena.de.

|July 12, 2021

Summary

This summary is machine-generated.

Pneumococcal vaccines like PPV23 and PCV13 offer protection against pneumonia. PCV13 provides longer-lasting immunity and herd protection, making it preferable for certain high-risk groups.

Keywords:

Community-acquired pneumonia Conjugate vaccine Herd immunity Polysaccharide vaccine Serotype 3

More Related Videos

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Related Experiment Videos

Last Updated: Oct 29, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Area of Science:

Immunology
Vaccinology
Infectious Diseases

Background:

Pneumococci are a leading cause of community-acquired pneumonia and vaccine-preventable deaths globally.
Pneumococcal polysaccharide vaccine 23 (PPV23) covers 23 serotypes but lacks immunologic memory and T-cell stimulation.
Pneumococcal conjugate vaccine 13 (PCV13) covers fewer serotypes but induces immunologic memory and mucosal immunity, offering herd protection.

Purpose of the Study:

To compare the efficacy and immunological memory of PPV23 and PCV13.
To inform vaccination recommendations for different populations, including immunocompromised individuals.

Main Methods:

Review of existing literature on pneumococcal vaccines (PPV23 and PCV13).
Analysis of vaccine characteristics, including serotype coverage, T-cell response, and immunologic memory induction.
Evaluation of current vaccination guidelines from the German Standing Commission on Vaccination Practices (STIKO).

Main Results:

PPV23 provides good protection against invasive pneumococcal disease but does not establish immunologic memory.
PCV13, despite fewer serotypes, induces immunologic memory and mucosal immunity, leading to herd-protective effects.
STIKO recommends PPV23 for individuals over 60 and those with comorbidities, with specific sequential vaccination protocols (PCV13 followed by PPV23) for immunocompromised patients.

Conclusions:

Sequential vaccination with PCV13 followed by PPV23 is recommended for immunocompromised individuals, those with chronic renal or liver failure due to increased infection risk and limited PPV23 efficacy.
PCV13 offers advantages in immunologic memory and herd protection compared to PPV23.
Vaccination strategies should consider individual risk factors and vaccine-specific immunological responses.